(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number
WO 2005/049600 A1

(51) International Patent Classification[7]: C07D 401/04, A61P 25/00, A61K 31/4439

(21) International Application Number: PCT/EP2004/012772

(22) International Filing Date: 10 November 2004 (10.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0326407.4 12 November 2003 (12.11.2003) GB

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ALVARO, Giuseppe [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37100 Verona (IT). DI FABIO, Romano [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37100 Verona (IT). GIOVANNINI, Riccardo [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37100 Verona (IT). PAIO, Alfredo [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37100 Verona (IT). TRANQUILLINI, Maria, Elvira [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37100 Verona (IT). MATTIOLI, Lucia [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37100 Verona (IT).

(74) Agent: GIDDINGS, Peter, John; GlaxoSmithKline, 980 Great West Road (CN925.1), Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

[Continued on next page]

(54) Title: BETA-LACTAMS FOR TREATMENT OF CNS DISORDERS



(I)

(i)



(ii)



(iii)



(iv)

(57) Abstract: The present invention relates to novel compounds of formula (I) wherein ---- represents a single or a double bond; R represents a radical selected from formulae i), ii), iii) and iv) in which R_1 is halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3; R_2 represents hydrogen or C_{1-4} alkyl; R_3 represents hydrogen, hydroxy or C_{1-4} alkyl; R_4 represents hydrogen or R_4 together with R_3 represents =O or $=CH_2$; R_5 represents phenyl, naphthyl, a 9 to 10 membered fused bicyclic heterocyclic group or a 5 or 6 membered heteroaryl group, wherein said groups are optionally substituted by 1 to 3 groups independently selected from trifluoromethyl, C_{1-4} alkyl, hydroxy, cyano, C_{1-4} alkoxy, trifluoromethoxy, halogen or $S(O)qC_{1-4}$ alkyl; R_6 and R_7 independently represent hydrogen, cyano, C_{1-4} alkyl; R_8 is $(CH_2)rR_{10}$; R_9 represents hydrogen, halogen, C_{3-7} cycloalkyl, hydroxy, nitro, cyano or C_{1-4} alkyl optionally substituted by one or two groups selected from halogen, cyano, hydroxy or C_{1-4} alkoxy; R_{10} represents hydrogen or C_{3-7} cycloalkyl; n represents 1 or 2; q is 0, 1 or 2; r is 0 or an integer from 1 to 4; or a pharmaceutically acceptable salt or a solvate thereof, process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of the serotonin reuptake transporter protein.

WO 2005/049600 A1